Bioidentical Hormone Therapy

Clarus Health's bioidentical hormone replacement therapy programme uses advanced multi-media testing — blood, urine, and saliva — to build a complete picture of hormonal balance before designing a personalised BHRT protocol. Testing covers estrogen and its metabolites, progesterone, testosterone, DHEA, cortisol, thyroid hormones, SHBG, adrenal function markers, and inflammatory indicators. Hormones are replaced using bioidentical formulations matched to the body's own molecular structure, available as pellets, injections, or topical creams. A three-step process — holistic intake, personalised protocol, and sustained monitoring — underpins every BHRT programme at Clarus.

Clarus Health's bioidentical hormone replacement therapy (BHRT) programme is designed around the principle that hormonal optimisation requires precision: accurate multi-media measurement, individualised prescribing, and ongoing monitoring rather than a one-size protocol applied to a symptom checklist. The programme is led by Dr. Anthony Kaveh, whose background in anesthesiology and functional medicine informs a deeply physiological approach to hormone management. Diagnostic testing within the BHRT programme goes well beyond a conventional sex hormone panel. Estrogen assessment includes not just estradiol and estrone but estrogen metabolites — particularly the 2-hydroxy and 16-hydroxy estrone pathways — providing insight into how estrogen is being processed and whether the balance of metabolites may be contributing to symptoms or health risks. Sex hormone binding globulin (SHBG) is measured to assess bioavailable (free) hormone fractions, as total hormone levels can be misleading when binding protein levels are dysregulated. The adrenal axis is evaluated through cortisol (ideally across the diurnal rhythm), DHEA-S, and aldosterone, recognising that adrenal imbalance frequently co-exists with and amplifies sex hormone dysregulation. Inflammatory markers including CRP and IL-6 are incorporated because chronic inflammation disrupts the HPG axis and reduces hormonal receptor sensitivity. Genomically, Clarus tests for variants in the COMT gene — which governs catechol estrogen clearance — and MTHFR, which affects folate metabolism and methylation capacity relevant to estrogen detoxification through the liver. These findings directly shape which hormone formulations, doses, and co-factor supplementation are prescribed. BHRT at Clarus is available in three delivery modalities: subcutaneous pellets (testosterone and estradiol), which provide a sustained, consistent release over three to six months without daily dosing burden; intramuscular or subcutaneous injections for testosterone and progesterone; and topical bioidentical creams for clients who prefer non-invasive daily application. Monitoring follows a structured cadence — retesting at defined intervals to adjust doses based on both objective lab markers and subjective symptom response. All prescriptions are compounded or sourced as bioidentical formulations structurally identical to the hormones naturally produced by the human body, as distinct from synthetic conjugated equine estrogens or progestins used in conventional HRT. Clarus accepts most major insurance plans including Anthem Blue Cross, Cigna, Aetna, Medicare, and United Healthcare, and medical financing is available for uninsured clients.